Patients with a high probability of HFpEF may experience greater benefits from atrial fibrillation ablation than those with a ...

PFA is a newer Afib ablation modality touted as reducing the risk of damaging nearby collateral structures, compared with ...

Kardium today announced one-year clinical trial results for its Globe PF pulsed field ablation (PFA) system for treating AFib ...

Kardium Inc., a private medical device company that’s advancing the way the world treats atrial fibrillation (AF), announced ...

Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of ...

With careful consideration of several factors, many patients can avoid an overnight stay, reducing costs without sacrificing ...

Subjects in the study were monitored using the LUX-Dx insertable cardiac monitor system to detect arrhythmia recurrence.

Catheter Ablation Devices for Atrial Fibrillation Market 2035, Driven by advanced devices, better clinical outcomes, and rising regulatory approvals.

Pulse Biosciences is developing nsPFA technology for cardiac ablation to treat AFib and for ablating benign thyroid nodules.

The biomedical market’s latest technology for treating irregular heartbeats has made its way to the Flathead Valley, bringing ...

Boston Scientific said that while tariffs pose “unfortunate” headwinds—which are poised to add about $200 million to the cost ...

Led by Farapulse founder Steven Mickelsen, Field has developed a pulsed field ablation device to tackle the dangerous heart ...